U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT07532473) titled 'REal World MAIA UK OutcomEs' on April 07.
Brief Summary: This study will describe the use of triplet therapy with daratumumab, lenalidomide and dexamethasone (DRd) in the treatment of for transplant ineligible (TIE) untreated myeloma outside of clinical trials and assess the associated clinical outcomes.
Study Start Date: July, 2026
Study Type: OBSERVATIONAL
Condition:
Myeloma
Recruitment Status: NOT_YET_RECRUITING
Sponsor: The Royal Wolverhampton Hospitals NHS Trust
Disclaimer: Curated by HT Syndication....